BRPI0808887A2 - Formulação farmacêutica tópica - Google Patents

Formulação farmacêutica tópica Download PDF

Info

Publication number
BRPI0808887A2
BRPI0808887A2 BRPI0808887-0A BRPI0808887A BRPI0808887A2 BR PI0808887 A2 BRPI0808887 A2 BR PI0808887A2 BR PI0808887 A BRPI0808887 A BR PI0808887A BR PI0808887 A2 BRPI0808887 A2 BR PI0808887A2
Authority
BR
Brazil
Prior art keywords
composition according
diclofenac
ester
polyhydric alcohol
nsaid
Prior art date
Application number
BRPI0808887-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Adrian Francis Davis
Original Assignee
Futura Medical Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Futura Medical Dev Ltd filed Critical Futura Medical Dev Ltd
Publication of BRPI0808887A2 publication Critical patent/BRPI0808887A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0808887-0A 2007-03-13 2008-02-15 Formulação farmacêutica tópica BRPI0808887A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0704846.5 2007-03-13
GBGB0704846.5A GB0704846D0 (en) 2007-03-13 2007-03-13 Topical pharmaceutical formulation
PCT/GB2008/000540 WO2008110741A2 (en) 2007-03-13 2008-02-15 Topical pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BRPI0808887A2 true BRPI0808887A2 (pt) 2014-09-02

Family

ID=37988913

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808887-0A BRPI0808887A2 (pt) 2007-03-13 2008-02-15 Formulação farmacêutica tópica

Country Status (21)

Country Link
US (1) US8541470B2 (enExample)
EP (2) EP2131813B1 (enExample)
JP (1) JP2010521442A (enExample)
CN (1) CN101663022A (enExample)
AU (1) AU2008224735B2 (enExample)
BR (1) BRPI0808887A2 (enExample)
CA (1) CA2680074C (enExample)
CO (1) CO6220926A2 (enExample)
DK (1) DK2131813T3 (enExample)
ES (1) ES2391914T3 (enExample)
GB (1) GB0704846D0 (enExample)
MX (1) MX2009009758A (enExample)
MY (1) MY149545A (enExample)
NZ (1) NZ579895A (enExample)
PL (1) PL2131813T3 (enExample)
PT (1) PT2131813E (enExample)
RU (1) RU2468794C2 (enExample)
SG (1) SG179480A1 (enExample)
TW (1) TWI367110B (enExample)
UA (1) UA100509C2 (enExample)
WO (1) WO2008110741A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3300721T4 (da) * 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
HK1205114A1 (en) 2012-04-12 2015-12-11 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
KR102235264B1 (ko) * 2013-01-14 2021-04-02 인퍼스트 헬스케어 리미티드 고용체 조성물들 및 심각한 통증에서의 이들의 용도
EP2943183A1 (en) * 2013-01-14 2015-11-18 InFirst Healthcare Limited Compositions and methods for treating severe pain
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
GB201502845D0 (en) * 2015-02-20 2015-04-08 Futura Medical Dev Ltd Topical pharmaceutical formulation
FR3041534B1 (fr) * 2015-09-30 2019-03-15 Vetoquinol Sa Composition de nettoyant auriculaire
GB201609968D0 (en) * 2016-06-07 2016-07-20 Futura Medical Dev Ltd Topical pharmaceutical formulation
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
CN110545796A (zh) * 2017-03-07 2019-12-06 耶路撒冷希伯来大学伊森姆研究发展有限公司 用于活性化合物的局部递送系统
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
GB2596286B (en) 2020-06-20 2023-01-25 Francis Davis Adrian Adherence to topical therapy
WO2022023348A1 (en) 2020-07-27 2022-02-03 Incanthera (R&D) Ltd Topical formulation
GB2597526A (en) 2020-07-27 2022-02-02 Incanthera R&D Ltd Topical formulation
GB202012836D0 (en) 2020-08-17 2020-09-30 Futura Medical Developments Ltd Topical composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06104624B2 (ja) 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
PE20011092A1 (es) 2000-02-14 2001-11-12 Procter & Gamble Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
AR041021A1 (es) * 2002-08-22 2005-04-27 Novartis Consumer Health Sa Composicion topica
US7132452B2 (en) * 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
WO2005027977A2 (en) * 2003-09-22 2005-03-31 Agis Industries (1983) Ltd. Diclofenac compositions for the treatment of skin disorders
EP1588697A1 (en) 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
US20050244522A1 (en) 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents

Also Published As

Publication number Publication date
NZ579895A (en) 2012-02-24
WO2008110741A8 (en) 2009-11-19
ES2391914T3 (es) 2012-12-03
CA2680074A1 (en) 2008-09-18
RU2009136228A (ru) 2011-04-20
AU2008224735A1 (en) 2008-09-18
WO2008110741A2 (en) 2008-09-18
TW200836769A (en) 2008-09-16
CO6220926A2 (es) 2010-11-19
EP2131813B1 (en) 2012-08-08
MX2009009758A (es) 2009-09-24
UA100509C2 (ru) 2013-01-10
SG179480A1 (en) 2012-04-27
MY149545A (en) 2013-09-13
EP2452671A2 (en) 2012-05-16
PT2131813E (pt) 2012-10-31
PL2131813T3 (pl) 2012-11-30
WO2008110741A3 (en) 2009-03-12
JP2010521442A (ja) 2010-06-24
CN101663022A (zh) 2010-03-03
RU2468794C2 (ru) 2012-12-10
US8541470B2 (en) 2013-09-24
EP2131813A2 (en) 2009-12-16
TWI367110B (en) 2012-07-01
GB0704846D0 (en) 2007-04-18
US20100099767A1 (en) 2010-04-22
AU2008224735B2 (en) 2013-04-18
CA2680074C (en) 2016-07-12
DK2131813T3 (da) 2012-10-29

Similar Documents

Publication Publication Date Title
BRPI0808887A2 (pt) Formulação farmacêutica tópica
CA2662434C (en) Topical nsaid compositions with increased solubility
ES2445443T3 (es) Solución tópica no acuosa de diclofenaco y proceso para la preparación de la misma
BR112020024768A2 (pt) Método para reduzir o intervalo de penetração cutânea de roflumilaste em um paciente, composição farmacêutica compreendendo roflumilaste e uma mistura emulsificante e composição farmacêutica compreendendo roflumilaste e pelo menos um emulsificante
PT1695708T (pt) Composição farmacêutica
CN106572970B (zh) 用于局部给药非甾体抗炎药以缓解肌肉骨骼疼痛的新型凝胶及其制备方法
PT96550A (pt) Processo para a libertacao percutanea de ibuprofeno utilizando gel hidro-alcoolico
PT503988E (pt) Composicoes para o tratamento de onicomicoses
ES2590258T3 (es) Preparación antiinflamatoria y analgésica para uso externo
JP5052558B2 (ja) ゲル軟膏
US10028927B2 (en) Topical pharmaceutical formulation
JP4195178B2 (ja) 消炎鎮痛外用剤
BR112015002041B1 (pt) Composições em gel adequadas para administração tópica de inibidores de cox-2
WO2017109761A1 (en) Topical composition for the treatment of acne
US11376213B2 (en) Topical pharmaceutical formulation
CA2500907A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
HK1170676A (en) Topical pharmaceutical formulation
BR102017011377B1 (pt) Composição e formulação tópica anestésica de (2e,8e)- n-isobutildeca- 2,8-dien-6-inamida e seu uso
TR2024002454A1 (tr) Topical compositions comprising nimesulide and diclofenac sodium and a salicylate
WO2022178604A1 (pt) Composição farmacêutica tópica espumável
HK1140954A (zh) 局部药物制剂

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]